

Risk factors and biofilm formation analyses of hospital-acquired infection of *Candida pelliculosa* in a neonatal intensive care unit

Zhijie Zhang¹, Yu Cao¹, Yanjian Li², Xufang Chen¹, Chen Ding², Yong Liu^{1*}

¹Department of Laboratory Medicine of Shengjing Hospital of China Medical University, 36 Sanhao Street, Heping District, Shenyang, China.

²College of Life and Health Sciences, Northeastern University, 195, Chuangxin Road, Hunnan District, Shenyang, China.

*Corresponding author:

Tel: +86-24-96615-72124

E-mail: liuy@sj-hospital.org (Yong Liu)

Table S1 Clinical characteristic of patients with *Candida pelliculosa* fungemia

No	Sex	Onset of candidemia (hospital day)	Ward	BW(g)/GA(WK)	AM	Apgar (1/5 min)	BSAU	PCBI	catheter tip culture	Inflammatory biomarker				MIC of Antifungal ($\mu\text{g/ml}$)					Antifungal therapy	outcome
										WBC($\times 10^9/\text{ml}$)	PLT($\times 10^9/\text{ml}$)	CRP (mg/L)	PCT (ng/ml)	FA	VRC	5-FC	AMB	ITR		
1	M	Oct 21,2017(21)	2	1234/28	33	7/9	Yes	No	NG	32.70 \uparrow	264	10.10 \uparrow	—	2	0.25	≤ 4	≤ 0.5	0.25	FCA	Sur
2	F	Nov 03,2017(22)	1	1157/28	35	9/10	Yes	No	NG	25.20 \uparrow	45 \downarrow	79.70 \uparrow	65.14 \uparrow	2	0.125	≤ 4	≤ 0.5	0.25	FCA	Sur
3	M	Nov 04,2017(42)	2	810/27	31	4/8	Yes	No	NG	14.05 \downarrow	84 \downarrow	94.70 \uparrow	—	4	0.25	≤ 4	≤ 0.5	0.25	FCA	Sur
4	F	Nov 05,2017(10)	2	1300/33	23	6/9	Yes	No	NG	11.38 \downarrow	130	9.86 \uparrow	—	2	0.125	≤ 4	≤ 0.5	0.25	FCA	Sur
5	F	Nov 05,2017(23)	1	846/28	37	5/9	Yes	No	CP	9.19 \downarrow	156	8.83 \uparrow	0.59 \uparrow	2	0.125	≤ 4	≤ 0.5	0.25	FCA	Sur
6	M	Nov 06,2017(18)	2	928/29	36	2/7	No	No	NG	13.83 \downarrow	312 \uparrow	16.10 \uparrow	—	2	0.125	≤ 4	≤ 0.5	0.125	FCA	Sur
7	F	Nov 05,2017(12)	2	1208/31	33	7/9	Yes	No	NG	6.46 \downarrow	111	7.90	3.10 \uparrow	2	0.125	≤ 4	≤ 0.5	0.25	FCA	Sur
8	M	Nov 15,2017(42)	2	823/27	38	4/7	Yes	No	CP	15.81	149	2.17	—	2	0.125	≤ 4	≤ 0.5	0.25	FCA	Sur
9	M	Nov 15,2017(22)	2	1600/28	38	6/9	No	No	NG	2.14 \downarrow	28 \downarrow	28.20 \uparrow	—	2	0.25	≤ 4	≤ 0.5	0.25	FCA	Sur
10	F	Nov 16,2017(13)	2	1170/32	35	7/9	Yes	No	CP	3.20 \downarrow	85 \downarrow	7.48	—	2	0.125	≤ 4	≤ 0.5	0.25	FCA	Sur
11	M	Nov 16,2017(29)	1	3415/35	20	5/9	Yes	No	NG	10.94 \downarrow	84 \downarrow	14.70 \uparrow	0.52 \uparrow	2	0.25	≤ 4	≤ 0.5	0.25	FCA	Sur
12	F	Nov 17,2017(11)	2	970/29	37	6/8	No	No	NG	11.26 \downarrow	202	1.31	—	4	0.25	≤ 4	≤ 0.5	0.25	FCA	Sur
13	M	Nov 21,2017(37)	1	735/26	38	2/7	Yes	No	CP	21.30 \uparrow	20 \downarrow	87.40 \uparrow	33.80 \uparrow	4	0.25	≤ 4	≤ 0.5	0.25	FCA	Sur
14	F	Nov 24,2017(19)	1	1287/29	38	9/9	Yes	Yes	CP	15.84	132	10.50 \uparrow	1.06 \uparrow	4	0.25	≤ 4	≤ 0.5	0.25	FCA	Sur
								(<i>Seipidemidis</i>)												
15	M	Nov 24,2017(17)	2	1226/28	40	6/8	Yes	No	CP	3.98 \downarrow	60 \downarrow	9.50 \uparrow	—	4	0.25	≤ 4	≤ 0.5	0.25	FCA	Sur
16	F	Nov 26,2017(32)	2	700/26	31	—	Yes	No	NG	4.10 \downarrow	136	17.30 \uparrow	—	2	0.25	≤ 4	≤ 0.5	0.5	FCA	Sur
17	M	Dec 14,2017(18)	1	1045/29	39	6/9	Yes	No	NG	2.78 \downarrow	107	13.10 \uparrow	0.59 \uparrow	2	0.125	≤ 4	≤ 0.5	0.25	FCA	Sur

18	M	Dec 14,2017(19)	2	1420/31	30	3/8	Yes	No	NG	6.19↓	159	10.70↑	—	2	0.125	≤4	≤0.5	0.25	FCA	Sur
19	M	Feb 17,2018(33)	1	955/28	30	3/9	Yes	No	NG	7.03↓	381↑	1.07	—	2	0.125	≤4	≤0.5	0.25	FCA	Sur
20	M	Aug 31,2018(22)	1	1214/32	36	8/10	Yes	No	CP	3.58↓	91↓	14.40↑	0.39	2	0.125	≤4	≤0.5	0.25	FCA	Sur
21	M	Sep 28,2018(10)	1	1117/26	31	5/9	Yes	No	NG	10.0↓	103	7.24	0.50↑	2	0.125	≤4	≤0.5	0.25	VRC	Sur

M=male, F=female, BW=birth weight, GA=gestational age (WK), AM=age of mother, BSAU=Broad spectrum antibiotics use before fungemia, PCBI=Previous or concomitant

bacteremic infection, NG= no growth, CP=*C. pelliculosa*, WBC=white blood cell, PLT= platelet, CRP=C reaction protein, PCT=procalcitonin ↑increased than reference

range↑decreased than reference range, Sur=survival, FCA= fluconazole, VRC= voriconazole, 5-FC=5-fluorocytosine, AMB=amphotericin B, ITR=itraconazole.